A post on the trial pitting Lilly's tirzepatide against dulaglutide for cardiovascular outcomes in people with type 2 diabetes.
Recap by typeshit. Post by Facebook on Facebook.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
A short Philstar Life item on PIONEER 8, a trial of oral semaglutide. The material gives only the title, so tap through for the details.
The Penn dermatologist told Fall Clinical 2026 that in the TOGETHER-PsO trial, tirzepatide plus ixekizumab cut blood pressure by about 8 to 10 mm Hg.
Investseekers points to Fierce Pharma's refreshed chart showing how the two oral obesity pill launches from Novo Nordisk and Eli Lilly are tracking over time.
Loading…